Raising HDL cholesterol has been a major research target for cardiovascular risk reduction, though established drug therapies resulting in substantial HDL-C increase are scarce and controversial.
This review highlights that while low HDL-C is a risk factor, simply raising HDL-C levels with current drugs has controversial benefits, shifting focus toward improving HDL particle functionality.
Since the first discovery of an inverse correlation between high-density lipoprotein-cholesterol (HDL-C) levels and coronary heart disease in the 1950s the life cycle of HDL, its role in atherosclerosis and the therapeutic modification of HDL-C levels have been major research topics. The Framingham study and others that followed could show that HDL-C is an independent cardiovascular risk factor and that the increase of HDL-C of only 10 mg·L(-1) leads to a risk reduction of 2-3%. While statin therapy and therefore low-density lipoprotein-cholesterol (LDL-C) reduction could lower coronary heart disease considerably; cardiovascular morbidity and mortality still occur in a significant portion of subjects already receiving therapy. Therefore, new strategies and therapies are needed to further reduce the risk. Raising HDL-C was thought to achieve this goal. However, established drug therapies resulting in substantial HDL-C increase are scarce and their effect is controversial. Furthermore, it is becoming increasingly evident that HDL particle functionality is at least as important as HDL-C levels since HDL particles not only promote reverse cholesterol transport from the periphery (mainly macrophages) to the liver but also exert pleiotropic effects on inflammation, haemostasis and apoptosis. This review deals with the biology of HDL particles, the established and future therapeutic options to increase HDL-C and discusses the results and conclusions of the most important studies published in the last years. Finally, an outlook on future diagnostic tools and therapeutic opportunities regarding coronary artery disease is given.
Ali et al. (Fri,) conducted a review in Cardiovascular disease. Raising HDL cholesterol was evaluated. Raising HDL cholesterol has been a major research target for cardiovascular risk reduction, though established drug therapies resulting in substantial HDL-C increase are scarce and controversial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: